GSK plc GSK
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Gross profit | $23.6B | +6% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Net income | $6.3B | +113% | FY ending Dec 31, 2025 |
| Research & development | $7.5B | +18% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 1 open-market buy ($27.9M) and 0 sales ($0) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Plc Gsk10% owner | Bought | 1,470,000 | $19.00 | $27.9M | Dec 11, 2025 |
Trades by members of Congress
4 members reported 5 buys and 6 sales since Nov 18, 2024. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Lisa C. McClain R | Sold | $1,001–$15K | Oct 31, 2025 | Nov 21, 2025 | Spouse |
| Lisa C. McClain R | Bought | $1,001–$15K | Oct 30, 2025 | Nov 21, 2025 | Spouse |
| Lisa C. McClain R | Sold | $1,001–$15K | Oct 30, 2025 | Nov 21, 2025 | Spouse |
| Val T. Hoyle D | Sold | $1,001–$15K | Sep 23, 2025 | Oct 10, 2025 | Spouse |
| Lisa C. McClain R | Bought | $1,001–$15K | Aug 4, 2025 | Sep 12, 2025 | Spouse |
| Val T. Hoyle D | Bought | $1,001–$15K | Nov 18, 2024 | Sep 12, 2025298 days later | Spouse |
| Robert B. Aderholt R | Sold | $1,001–$15K | Jul 28, 2025 | Sep 10, 2025 | Self |
| Lisa C. McClain R | Sold | $1,001–$15K | Jun 24, 2025 | Aug 13, 202550 days later | Spouse |
| Lisa C. McClain R | Bought | $1,001–$15K | Jun 17, 2025 | Aug 13, 202557 days later | Spouse |
| Bruce Westerman R | Sold | $1,001–$15K | Apr 21, 2025 | May 12, 2025 | Self |
| Bruce Westerman R | Bought | $1,001–$15K | Mar 3, 2025 | Apr 16, 2025 | Self |
Latest SEC filings
- News filing (foreign) 6-K · Oct 28, 2026
- News filing (foreign) 6-K · Oct 26, 2026
- News filing (foreign) 6-K · Oct 26, 2026
- News filing (foreign) 6-K · Oct 26, 2026
- News filing (foreign) 6-K · Oct 26, 2026
- News filing (foreign) 6-K · Oct 21, 2026
- News filing (foreign) 6-K · Oct 19, 2026
- News filing (foreign) 6-K · Oct 19, 2026
- News filing (foreign) 6-K · Oct 15, 2026
- News filing (foreign) 6-K · Oct 14, 2026
- News filing (foreign) 6-K · Oct 13, 2026
- News filing (foreign) 6-K · Oct 13, 2026
- News filing (foreign) 6-K · Oct 8, 2026
- News filing (foreign) 6-K · Oct 6, 2026
- News filing (foreign) 6-K · Oct 1, 2026
- News filing (foreign) 6-K · Sep 24, 2026
- News filing (foreign) 6-K · Sep 22, 2026
- News filing (foreign) 6-K · Sep 15, 2026
- News filing (foreign) 6-K · Sep 15, 2026
- News filing (foreign) 6-K · Sep 14, 2026
- News filing (foreign) 6-K · Sep 14, 2026
- News filing (foreign) 6-K · Sep 11, 2026
- News filing (foreign) 6-K · Sep 10, 2026
- News filing (foreign) 6-K · Sep 10, 2026
- News filing (foreign) 6-K · Sep 9, 2026
About GSK plc
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- London
- Incorporated in
- United Kingdom
- Exchange
- NYSE
- Also trades as
- GLAXF
- Filer size
- Large accelerated filer
- Formerly
- GLAXOSMITHKLINE PLC
- SEC company number (CIK)
- 1131399
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.